LINQURE
Live / Registered — Registered (as of 07 May 2024)
What this means for you
Registered since 07 May 2024. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 90736220
- Registration number
- 7376828
- Mark type
- Stylized text
- Filed
- 26 May 2021
- Published for opposition
- 19 Jul 2022
- Registered
- 07 May 2024
- Attorney of record
- Julianne Abelman
Goods and services
- Class 005 — Pharmaceuticals: Medicinal preparations for the diagnosis, treatment or prevention of Central Nervous System diseases, Liver diseases, Neuromuscular diseases and Cardiovascular diseases, namely, viral systems, gene therapy systems, nucleic acid delivery systems, viral vectors, non-viral vectors, gene therapy vectors, nucleic acid delivery vectors, and cells transformed by viral vectors, non-viral vectors, gene therapy vectors or nucleic acid delivery vectors; Viral systems, gene therapy systems, nucleic acid delivery systems for medical purposes, namely, medicines for the diagnosis, treatment or prevention of Central Nervous System diseases, Liver diseases, Neuromuscular diseases and Cardiovascular diseases; clinical medical reagents for use in nucleic acid based therapy, gene therapy, cell therapy, gene diagnosis and gene testing
- Class 042 — Scientific and technological services: Research, product development and consultancy in the field of biotechnology, biologics, medical science, chemistry and biochemistry; Research and product development in the field of pharmaceutics, namely, pharmaceutics in the field of gene therapy
- Class 044 — Medical, beauty and agricultural services: Gene and nucleic acid delivery, gene and nucleic acid transfer, gene and nucleic acid regulation and gene and nucleic acid modulation for the treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, inflammatory and auto-immune diseases, vascular disorders, inherited disorders, genetic disorders and single gene disorders; Consultancy in the field of pharmaceutics, namely, pharmaceutics in the field of gene therapy
Owner
- UNIQURE BIOPHARMA B.V., AMSTERDAM, NL
- uniQure IP B.V., Amsterdam, NL
- uniQure IP B.V., Amsterdam, NL
- uniQure IP B.V., Amsterdam, NL
Prosecution history
- 11 Jun 2025 — AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
- 04 Jun 2025 — TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
- 04 Jun 2025 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 04 Jun 2025 — TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
- 04 Jun 2025 — ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
- 04 Jun 2025 — TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
- 04 Jun 2025 — APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
- 04 Jun 2025 — TEAS CHANGE OF OWNER ADDRESS RECEIVED
- 07 May 2024 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 07 May 2024 — REGISTERED-PRINCIPAL REGISTER
- 27 Jan 2023 — POST PUBLICATION AMENDMENT - ENTERED
- 26 Jan 2023 — EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
- 25 Jan 2023 — ASSIGNED TO PETITION STAFF
- 12 Jan 2023 — TEAS POST PUBLICATION AMENDMENT RECEIVED
- 18 Aug 2022 — EXTENSION OF TIME TO OPPOSE RECEIVED